Table 1. Demographics and basic characteristics of the primary and replication cohorts.
Primary: the primary cohort from central Pennsylvania that was used to develop the DiaRem score prediction tool. AZ: the first replication cohort from the Scottsdale area in Arizona. PA: the second replication cohort from central Pennsylvania. The data shown are at 14 months following RYGB surgery, in all three cases. ISA: insulin sensitizing agent. (Age: years; HbA1c: percent; Serum insulin: μU/mL).
| Primary cohort | AZ cohort | PA cohort | P-value | |
|---|---|---|---|---|
|
| ||||
| Sample size | 690 | 276 | 113 | - |
|
| ||||
| Geographic location | Central PA | Scottsdale, AZ | Central PA | - |
|
| ||||
| % Female | 73% | 68% | 74% | 0·272 |
|
| ||||
| % Caucasian | 97% | 89% | 96% | <0·0001 |
|
| ||||
| Age (years): <40 (%) | 14% | 13% | 15% | |
| 40–49 | 30% | 34% | 32% | 0·119 |
| 50–59 | 37% | 41% | 36% | |
| 60+ | 19% | 11% | 17% | |
|
| ||||
| Pre-surgery BMI (kg/m2), mean (SD) | 49·4 (8·3) | 48·4 (8·3) | 49·5 (9·3) | 0·200 |
|
| ||||
| HbA1c (%): <6·5 | 38% | 28% | 43% | |
| 6·5–6·9 | 16% | 18% | 14% | 0·056 |
| 7·0–8·9 | 30% | 39% | 34% | |
| 9·0+ | 15% | 15% | 9% | |
|
| ||||
| Metformin use | 78% | 74% | 83% | 0·103 |
|
| ||||
| Sulfonylureas use | 31% | 33% | 32% | 0·851 |
|
| ||||
| Other ISA | 32% | 41% | 20% | 0·0004 |
|
| ||||
| Insulin use | 36% | 28% | 38% | 0·032 |
|
| ||||
| Serum Insulin (μU/mL): >=30 | 72% | 71% | 71% | 0·868 |
|
| ||||
| DiaRem score: 0–2 | 27% | 18% | 27% | |
| 3–7 | 30% | 43% | 32% | |
| 8–12 | 10% | 14% | 11% | 0·0031 |
| 13–17 | 24% | 17% | 22% | |
| 18–22 | 8% | 7% | 8% | |